The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus

Jin Ha Lee, Tae Il Kim, Soung Min Jeon, Sung Pil Hong, JaeHee Cheon, Won Ho Kim

Research output: Contribution to journalReview article

114 Citations (Scopus)

Abstract

Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on clinical outcomes of colorectal cancer (CRC) are not defined. This study aimed to evaluate the association between metformin use and mortality of CRC in diabetic patients. We identified 595 patients who were diagnosed both CRC and diabetes mellitus. Patients were compared by two groups; 258 diabetic patients taking metformin and 337 diabetic patients not taking metformin. Patient's demographics, clinical characteristics, overall mortality and CRC-specific mortality were analyzed. After a median follow-up of 41 months, there were 71 total deaths (27.5%) and 55 CRC-specific deaths (21.3%) among 258 patients who used metformin, compared with 136 total deaths (40.4%) and 104 CRC-specific deaths (30.9%) among 337 patients who did not use metformin. Metformin use was associated with decreased overall mortality (p = 0.018) and CRC-specific mortality (p = 0.042) by univariate analysis. After adjustment for clinically relevant factors, metformin use showed lower risk of overall mortality (HR, 0.66; 95% CI 0.476-0.923; p = 0.015) and CRC-specific mortality (HR, 0.66; 95% CI 0.45-0.975; p = 0.037) in CRC patients with diabetes. Metformin use in CRC patients with diabetes is associated with lower risk of CRC-specific and overall mortality.

Original languageEnglish
Pages (from-to)752-759
Number of pages8
JournalInternational Journal of Cancer
Volume131
Issue number3
DOIs
Publication statusPublished - 2012 Aug 1

Fingerprint

Metformin
Colorectal Neoplasms
Diabetes Mellitus
Survival
Mortality
Demography

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lee, Jin Ha ; Kim, Tae Il ; Jeon, Soung Min ; Hong, Sung Pil ; Cheon, JaeHee ; Kim, Won Ho. / The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. In: International Journal of Cancer. 2012 ; Vol. 131, No. 3. pp. 752-759.
@article{3613276324df40c691f03c9df2bef6a3,
title = "The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus",
abstract = "Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on clinical outcomes of colorectal cancer (CRC) are not defined. This study aimed to evaluate the association between metformin use and mortality of CRC in diabetic patients. We identified 595 patients who were diagnosed both CRC and diabetes mellitus. Patients were compared by two groups; 258 diabetic patients taking metformin and 337 diabetic patients not taking metformin. Patient's demographics, clinical characteristics, overall mortality and CRC-specific mortality were analyzed. After a median follow-up of 41 months, there were 71 total deaths (27.5{\%}) and 55 CRC-specific deaths (21.3{\%}) among 258 patients who used metformin, compared with 136 total deaths (40.4{\%}) and 104 CRC-specific deaths (30.9{\%}) among 337 patients who did not use metformin. Metformin use was associated with decreased overall mortality (p = 0.018) and CRC-specific mortality (p = 0.042) by univariate analysis. After adjustment for clinically relevant factors, metformin use showed lower risk of overall mortality (HR, 0.66; 95{\%} CI 0.476-0.923; p = 0.015) and CRC-specific mortality (HR, 0.66; 95{\%} CI 0.45-0.975; p = 0.037) in CRC patients with diabetes. Metformin use in CRC patients with diabetes is associated with lower risk of CRC-specific and overall mortality.",
author = "Lee, {Jin Ha} and Kim, {Tae Il} and Jeon, {Soung Min} and Hong, {Sung Pil} and JaeHee Cheon and Kim, {Won Ho}",
year = "2012",
month = "8",
day = "1",
doi = "10.1002/ijc.26421",
language = "English",
volume = "131",
pages = "752--759",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. / Lee, Jin Ha; Kim, Tae Il; Jeon, Soung Min; Hong, Sung Pil; Cheon, JaeHee; Kim, Won Ho.

In: International Journal of Cancer, Vol. 131, No. 3, 01.08.2012, p. 752-759.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus

AU - Lee, Jin Ha

AU - Kim, Tae Il

AU - Jeon, Soung Min

AU - Hong, Sung Pil

AU - Cheon, JaeHee

AU - Kim, Won Ho

PY - 2012/8/1

Y1 - 2012/8/1

N2 - Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on clinical outcomes of colorectal cancer (CRC) are not defined. This study aimed to evaluate the association between metformin use and mortality of CRC in diabetic patients. We identified 595 patients who were diagnosed both CRC and diabetes mellitus. Patients were compared by two groups; 258 diabetic patients taking metformin and 337 diabetic patients not taking metformin. Patient's demographics, clinical characteristics, overall mortality and CRC-specific mortality were analyzed. After a median follow-up of 41 months, there were 71 total deaths (27.5%) and 55 CRC-specific deaths (21.3%) among 258 patients who used metformin, compared with 136 total deaths (40.4%) and 104 CRC-specific deaths (30.9%) among 337 patients who did not use metformin. Metformin use was associated with decreased overall mortality (p = 0.018) and CRC-specific mortality (p = 0.042) by univariate analysis. After adjustment for clinically relevant factors, metformin use showed lower risk of overall mortality (HR, 0.66; 95% CI 0.476-0.923; p = 0.015) and CRC-specific mortality (HR, 0.66; 95% CI 0.45-0.975; p = 0.037) in CRC patients with diabetes. Metformin use in CRC patients with diabetes is associated with lower risk of CRC-specific and overall mortality.

AB - Metformin use has been associated with decreased cancer risk and mortality. However, the effects of metformin on clinical outcomes of colorectal cancer (CRC) are not defined. This study aimed to evaluate the association between metformin use and mortality of CRC in diabetic patients. We identified 595 patients who were diagnosed both CRC and diabetes mellitus. Patients were compared by two groups; 258 diabetic patients taking metformin and 337 diabetic patients not taking metformin. Patient's demographics, clinical characteristics, overall mortality and CRC-specific mortality were analyzed. After a median follow-up of 41 months, there were 71 total deaths (27.5%) and 55 CRC-specific deaths (21.3%) among 258 patients who used metformin, compared with 136 total deaths (40.4%) and 104 CRC-specific deaths (30.9%) among 337 patients who did not use metformin. Metformin use was associated with decreased overall mortality (p = 0.018) and CRC-specific mortality (p = 0.042) by univariate analysis. After adjustment for clinically relevant factors, metformin use showed lower risk of overall mortality (HR, 0.66; 95% CI 0.476-0.923; p = 0.015) and CRC-specific mortality (HR, 0.66; 95% CI 0.45-0.975; p = 0.037) in CRC patients with diabetes. Metformin use in CRC patients with diabetes is associated with lower risk of CRC-specific and overall mortality.

UR - http://www.scopus.com/inward/record.url?scp=84861576077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861576077&partnerID=8YFLogxK

U2 - 10.1002/ijc.26421

DO - 10.1002/ijc.26421

M3 - Review article

VL - 131

SP - 752

EP - 759

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -